Feature genes of hepatitis B virus-positive hepatocellular carcinoma, established by its molecular discrimination approach using prediction analysis of microarray.

[1]  X. Wang,et al.  Cancer‐associated molecular signature in the tissue samples of patients with cirrhosis , 2004, Hepatology.

[2]  Andrea Tannapfel,et al.  Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays , 2003, The Journal of pathology.

[3]  N. Iizuka,et al.  Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis , 2003, Oncogene.

[4]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[5]  N. Iizuka,et al.  MECHANISMS OF DISEASE Mechanisms of disease , 2022 .

[6]  Roger E Bumgarner,et al.  Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. , 2003, Cancer research.

[7]  S. Ishikawa,et al.  Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling , 2003, International journal of cancer.

[8]  K. Matsushima,et al.  Gene expression profile analysis of the mouse liver during bacteria-induced fulminant hepatitis by a cDNA microarray system. , 2002, Biochemical and biophysical research communications.

[9]  H. McLeod,et al.  Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. , 2002, International journal of oncology.

[10]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[11]  N. Doggett,et al.  Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. , 2002, Genomics.

[12]  N. O’Callaghan,et al.  CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. , 2002, Cancer research.

[13]  Xin Chen,et al.  Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. , 2002, Cancer research.

[14]  Moritoshi Kinoshita,et al.  Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci , 2002, Hepatology.

[15]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[16]  N. Iizuka,et al.  Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. , 2002, Cancer research.

[17]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[18]  Chris Cheadle,et al.  Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. , 2002, Cancer research.

[19]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Lemon,et al.  Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells , 2002, Hepatology.

[21]  S. Thorgeirsson,et al.  Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer , 2002, Hepatology.

[22]  Yiannis Koutalos,et al.  Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. , 2002, Cancer research.

[23]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[25]  M. Manns,et al.  Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. , 2002, Molecular pharmacology.

[26]  K. Munger,et al.  Id Proteins - Tumor Markers or Oncogenes? , 2002, Cancer biology & therapy.

[27]  K. Buetow,et al.  Significance of Genetic Variation at the Glutathione S-Transferase M1 and NAD(P)H:Quinone Oxidoreductase 1 Detoxification Genes in Breast Cancer Development , 2002, Oncology.

[28]  G. Fu,et al.  Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Shousha,et al.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. , 2001, Journal of clinical pathology.

[31]  P. Kelly,et al.  Mutational analysis of the PRL receptor gene in human breast tumors with differential PRL receptor protein expression. , 2001, The Journal of clinical endocrinology and metabolism.

[32]  I. Ng,et al.  Expression of p27KIP1 and p21WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis , 2001 .

[33]  U. Scherf,et al.  Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling , 2001, Cancer.

[34]  S. Bornstein,et al.  Expression and distribution of the prolactin receptor in normal rat liver and in experimental liver cirrhosis. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[35]  R. Alani,et al.  Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Watson,et al.  Defects of DNA mismatch repair in human prostate cancer. , 2001, Cancer research.

[37]  P. Farnham,et al.  Expression profiling and identification of novel genes in hepatocellular carcinomas , 2001, Oncogene.

[38]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[39]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[41]  X. Wu,et al.  Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. , 2001, Cancer research.

[42]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[43]  G. Morgan,et al.  Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. , 2001, Blood.

[44]  S. Gullans,et al.  Differential gene expression profiling in human brain tumors. , 2001, Physiological genomics.

[45]  A. Schauer,et al.  Analysis of the DNA mismatch repair proteins expression in malignant melanomas. , 2000, Anticancer research.

[46]  K. Engeland,et al.  Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma , 2000, International journal of cancer.

[47]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[48]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[49]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[50]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.

[52]  S. Aebi,et al.  Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. , 1997, Journal of the National Cancer Institute.

[53]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[54]  B. Vogelstein,et al.  Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. , 2001, Cancer research.

[55]  H. Mackay,et al.  Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  H. Otto,et al.  “Slow-down” of the intrahepatic bile duct development between the 2nd and the 3rd trimester of gestation , 2000 .

[57]  C. J. Huberty,et al.  Applied Discriminant Analysis , 1994 .